Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
15 Juillet 2024 - 7:30AM
Dijon, France, July 15th
2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext:
ALCJ), a specialty pharma company in advanced phases of development
and registration for ZEPIZURE®, its
emergency treatment for the management of epileptic crises based on
its award-winning needle-free auto-injector ZENEO®, announces it
will attend the H.C. Wainwright 26th Annual Global Investment
Conference, taking place in New York September 9-11, 2024.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma companybased in
France and the U.S. It is in advanced regulatory development for
ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a
$60 million contract with the U.S.Biomedical Advanced Research and
Development Authority (BARDA). ZEPIZURE® is based on the Company’s
award-winning needle-free autoinjector ZENEO®, designed to enable
patients and untrained caregivers to easily and instantly deliver
emergency medication via intramuscularinjection on bare skin or
even through clothing. The Company’s other products in
developmentinclude rescue therapies for allergic shocks, adrenal
insufficiencies, opioid overdose and asthmaattacks.
For further information, please contact:
|
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
Crossject (EU:ALCJ)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Crossject (EU:ALCJ)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
